Atara Biotherapeutics, Inc.
tabelecleucel
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)
Resolved
179days ago
FDA decision · Jan 9, 2026
What's at stake
An FDA complete response letter on tabelecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is in focus around Jan 9, 2026.
Primary source
· SEC 8-K
verified 14h ago
“the Complete Response Letter received on January 9, 2026”